U.S. market Closed. Opens in 12 hours 24 minutes

RENB | Renovaro Biosciences Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-06-302022-06-302021-06-302020-06-302019-06-30
RevenueN/AN/AN/AN/AN/A
Cost of Revenue113.50K123.59K391.42K366.27K71.71K
Gross Profit-113.50K-123.59K-391.42K-366.27K-71.71K
Operating Expenses19.60M22.83M23.40M11.92M10.92M
Selling, General & Admin15.32M14.33M7.56M7.12M8.42M
Research & Development4.17M8.37M15.72M4.69M2.50M
Other Operating ExpensesN/AN/AN/AN/AN/A
Operating Income-38.56M-116.08M-23.40M-11.92M-10.99M
Other Expenses / Income-19.38M-90.36M-3.08M561.39K-7.03M
Before Tax Income-39.68M-113.43M-26.85M-11.42M-18.02M
Income Tax Expenses706.96K34.00-125.28K104.28K1.00
Net Income-39.68M-113.43M-26.72M-11.42M-18.02M
Interest Expenses706.96K372.84K379.61K104.28K43.00
Basic Shares Outstanding56.27M52.53M47.17M46.33M37.55M
Diluted Shares Outstanding56.27M52.53M47.17M46.33M37.55M
EBITDA-19.48M-22.58M-23.27M-11.51M-10.92M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-38.27M-113.06M-26.47M-11.21M-18.02M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-06-302022-06-302021-06-302020-06-302019-06-30
An error has occurred. This application may no longer respond until reloaded. Reload 🗙